{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Giri AK"],"funding":["Mary och Georg C. Ehrnrooths Stiftelse","Research Council of Finland","Otto A. Malm Foundation","Maud Kuistila Memorial Foundation"],"pagination":["64"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11969768"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by poor survival outcomes. Further, due to the extreme molecular heterogeneity of the disease, drug treatment response varies from patient to patient. The variability of drug response can cause unnecessary treatment in more than half of the patients with no or partial therapy responses leading to severe side effects, monetary as well as time loss. Understanding the genetic risk factors underlying the drug response in AML can help with improved prediction of treatment responses and identification of biomarkers in addition to mechanistic insights to monitor treatment response. Here, we report the results of the first Exome-Wide Association Study (EWAS) of ex-vivo drug response performed to date with 175 AML cases and 47"],"journal":["BMC medical genomics"],"pubmed_title":["Exome-wide association study reveals 7 functional variants associated with ex-vivo drug response in acute myeloid leukemia patients."],"pmcid":["PMC11969768"],"funding_grant_id":["325999","2021-0270C","16-16116-11","202210066","359690"],"pubmed_authors":["Tripathi G","Kyriakidis K","Lin J","Giri AK","Almusa H"],"additional_accession":[]},"is_claimable":false,"name":"Exome-wide association study reveals 7 functional variants associated with ex-vivo drug response in acute myeloid leukemia patients.","description":"Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by poor survival outcomes. Further, due to the extreme molecular heterogeneity of the disease, drug treatment response varies from patient to patient. The variability of drug response can cause unnecessary treatment in more than half of the patients with no or partial therapy responses leading to severe side effects, monetary as well as time loss. Understanding the genetic risk factors underlying the drug response in AML can help with improved prediction of treatment responses and identification of biomarkers in addition to mechanistic insights to monitor treatment response. Here, we report the results of the first Exome-Wide Association Study (EWAS) of ex-vivo drug response performed to date with 175 AML cases and 47","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-05-23T03:09:41.558Z","creation":"2025-07-01T03:05:20.146Z"},"accession":"S-EPMC11969768","cross_references":{"pubmed":["40186177"],"doi":["10.1186/s12920-025-02130-7"]}}